3-氨基-5-羟基苯甲酸甲酯 | 67973-80-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-5-羟基苯甲酸甲酯
• 英文名称: 3-amino-5-hydroxy-benzoic acid methyl ester
• 英文别名: 3-hydroxy-5-aminobenzoic acid methyl ester；methyl 3-amino-5-hydroxybenzoate；3-amino-5-hydroxybenzoic acid methyl ester；5-amino-3-hydroxybenzoic acid methyl ester；methyl 3-hydroxy-5-aminobenzoate
• CAS: 67973-80-2
• 化学式: C₈H₉NO₃
• mdl: MFCD09263220
• 分子量: 167.164
• InChiKey: DMNGQQIFOZYIRA-UHFFFAOYSA-N

物化性质

• 熔点：
  124.5 °C
• 沸点：
  376.4±22.0 °C(Predicted)
• 密度：
  1.305±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3-amino-5-hydroxybenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-amino-5-hydroxybenzoate
CAS number: 67973-80-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H9NO3
Molecular weight: 167.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-5-羟基苯甲酸甲酯 在 盐酸 、 sodium nitrite 、 potassium iodide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.42h， 以56%的产率得到3-羧基-5-碘苯甲酸甲酯
  参考文献：
  名称：

  Structure–activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy

  摘要：

  The optimization of our lead GK activator 2a to 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl) phenoxy]-N-1,3-thiazol-2-ylbenzamide (6g), a potent GK activator with good oral availability, is described, including to uncouple the relationship between potency and hydrophobicity. Following oral administration, this compound exhibited robust glucose lowering in diabetic model rodents. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.04.040
• 作为产物：
  描述：

  甲醇 、 3-氨基-5-羟基苯甲酸 在 盐酸 作用下， 生成 3-氨基-5-羟基苯甲酸甲酯
  参考文献：
  名称：

  [EN] THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES
  [FR] ISOMERE R DE COMPOSES D'ACIDES AMINES BETA EN TANT QUE DERIVES ANTAGONISTES DU RECEPTEUR DES INTEGRINES

  摘要：

  本发明涉及一类由公式(I)表示的化合物或其药用可接受的盐，包含公式(I)化合物的药物组合物，以及在不显著抑制αVβ6整合素的情况下选择性抑制或拮抗αVβ3和/或αVβ5整合素的方法。

  公开号：

  WO2004060376A1

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• [EN] PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES<br/>[FR] COMPOSES PYRROLIQUES DESTINES AU TRAITEMENT DE MALADIES INDUITES PAR PROSTAGLANDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2003101959A1

  公开（公告）日：2003-12-11

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine, in particular their use in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

  式(I)的化合物或其药学上可接受的衍生物：其中A、R1、R2a、R2b、Rx、R8和R9如规范中所定义，一种制备这种化合物的方法，包括这种化合物的药物组合物以及这种化合物在医学中的用途，特别是它们在治疗前列腺素介导的疾病，如疼痛、炎症、免疫、骨骼、神经退行性或肾脏疾病中的用途。
• Two Approaches to the Aromatic Core of the Aminonaphthoquinone Antibiotics
  作者：Christopher C. Nawrat、Leoni I. Palmer、Alexander J. Blake、Christopher J. Moody

  DOI：10.1021/jo400737f

  日期：2013.6.7

  Two complementary approaches are presented for the synthesis of the quinone chromophores of the naphthoquinone ansamycins and related natural products. The first involves the use of an improved protocol for the manganese(III) acetate mediated cyclization of 5-aryl-1,3-dicarbonyl compounds to β-naphthols, leading to the simple, scalable preparation of building blocks suitable for the synthesis of naturally

  提出了两种互补的方法来合成萘醌安沙霉素和相关天然产物的醌发色团。首先涉及使用改进的方案，以乙酸锰（III）介导的5-芳基-1,3-二羰基化合物环化成β-萘酚，从而导致可简单，可扩展地制备适合天然合成的结构单元发生氨基萘醌。第二种方法涉及一系列新的含酯的Danishefsky型二烯与N保护的氨基苯醌的Diels-Alder反应，以更快速地获得相似的中间体。
• [EN] NADPH OXIDASE 4 INHIBITORS<br/>[FR] INHIBITEURS DE LA NADPH OXYDASE 4
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2016207785A1

  公开（公告）日：2016-12-29

  The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.

  该发明涉及Formula (I)的2,5-二取代苯并噁唑和苯并噻唑衍生物，其中L、X、Y和环(A)如描述中所述，它们的制备以及它们作为药用活性化合物的用途。这些化合物可能对预防或治疗与受损的活性氧自由基（ROS）产生相关的疾病或紊乱，以及预防或治疗各种纤维化疾病具有用处。
• HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM
  申请人：Dams Géry Karel Julia

  公开号：US20100280268A1

  公开（公告）日：2010-11-04

  The present invention concerns a fluorescence resonance energy transfer based high throughput test system to measure the formation of the HIV gp41 six-helix bundle. In a first embodiment the current invention relates to a homogeneous time resolved fluorescence-based test system comprising a first helical polypeptide consisting essentially of the sequence of IQN36 (SEQ ID NO:1); a second helical polypeptide consisting essentially of the sequence of C34 (SEQ ID NO: 2) wherein said IQN36 is labeled with a light emitting fluorophore and said C34 is labeled with an ultra-violet excitable fluorophore.

  该发明涉及一种基于荧光共振能量转移的高通量测试系统，用于测量HIV gp41六螺旋束的形成。在第一实施例中，当前发明涉及一种基于均匀时间分辨荧光的测试系统，包括基本上由IQN36序列（SEQ ID NO:1）组成的第一螺旋多肽；基本上由C34序列（SEQ ID NO:2）组成的第二螺旋多肽，其中所述的IQN36标记有发光荧光团，所述的C34标记有紫外激发荧光团。

表征谱图